Needham Reiterates Buy on Autolus Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Autolus Therapeutics (NASDAQ:AUTL) and maintained a $9 price target.
June 03, 2024 | 10:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Autolus Therapeutics (NASDAQ:AUTL) and maintained a $9 price target.
The reiteration of a Buy rating and the maintenance of a $9 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100